Arikayce inhaled amikacin deveoper Insmed Incorporated has announced the appointments of Paolo Tombesi as Chief Financial Officer, Paul Streck as Chief Medical Officer, and Eugene Sullivan as Chief Product Strategy Officer.
Tombesi was most recently VP and Chief Financial and Administrative Officer of Novartis Pharmaceuticals Corporation, and Streck was most recently VP, Global Medical Specialty Franchise, Immuno-inflammation at GSK. Sullivan, a former FDA Deputy Director of the Division of Pulmonary and Allergy Products, joined Insmed as Chief Medical and Scientific Officer in 2015.
Insmed President and CEO Will Lewis said, “These management changes will strengthen our already solid leadership team and add critical skills to our organization as we collectively advance the clinical development of our portfolio and prepare for the potential commercialization of liposomal amikacin for inhalation.”
Arikayce is currently in Phase 3 development for the treatment of nontuberculous mycobacteria (NTM) lung infections. In 2014, Insmed submitted an MAA for the inhalation solution based on Phase 2 data, but the company withdrew the application in mid-2016 and said that it planned to resubmit after Phase 3 data becomes available.
Read the Insmed press release.
